Literature DB >> 25686808

Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.

Tri Giang Phan1, Georgina V Long2, Richard A Scolyer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25686808     DOI： 10.1038/icb.2015.12

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


× No keyword cloud information.
  15 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

4.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Authors:  Mahesh Yadav; Suchit Jhunjhunwala; Qui T Phung; Patrick Lupardus; Joshua Tanguay; Stephanie Bumbaca; Christian Franci; Tommy K Cheung; Jens Fritsche; Toni Weinschenk; Zora Modrusan; Ira Mellman; Jennie R Lill; Lélia Delamarre
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 9.  The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies.

Authors:  Bernd Krone; Klaus F Kölmel; John M Grange
Journal:  BMC Cancer       Date:  2014-08-16       Impact factor: 4.430

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
View more
  6 in total

1.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

2.  Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction.

Authors:  Dading Huang; Wei Wen; Xiao Liu; Yang Li; John Z H Zhang
Journal:  RSC Adv       Date:  2019-05-14       Impact factor: 4.036

Review 3.  The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation.

Authors:  Drenka Trivanović; Jelena Krstić; Ivana Okić Djordjević; Slavko Mojsilović; Juan Francisco Santibanez; Diana Bugarski; Aleksandra Jauković
Journal:  Mediators Inflamm       Date:  2016-08-18       Impact factor: 4.711

4.  PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.

Authors:  Xin Sun; Xiao Yan; Wei Zhuo; Jinke Gu; Ke Zuo; Wei Liu; Li Liang; Ya Gan; Gang He; Hua Wan; Xiaojun Gou; Hubing Shi; Jianping Hu
Journal:  Int J Mol Sci       Date:  2018-07-07       Impact factor: 5.923

5.  Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.

Authors:  Marina Martinez; Soyeon Kim; Naomi St Jean; Shaun O'Brien; Lurong Lian; Jing Sun; Raluca I Verona; Edmund Moon
Journal:  Oncoimmunology       Date:  2021-01-20       Impact factor: 7.723

6.  Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.

Authors:  Suliman Almahmoud; Haizhen A Zhong
Journal:  Int J Mol Sci       Date:  2019-09-19       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.